In Brief: Hi-Tech Pharmacal, OTC firm warned on water tests, John Taylor to leave FDA, NAD and ASA review claims
This article was originally published in The Tan Sheet
Hi-Tech Pharmacal profits plummet; FDA warns OTC firm about GMPs; John Taylor to leave FDA; NAD refers claims for Vysera-CLS to FTC; Circulation Patch It claims lack support – ASA; and U.K. liquid OTC recalls.
You may also be interested in...
The ruling in US District Court for the Eastern New York District notes a Supreme Court decision in January in a separate case that also focused on settlement offers rejected by plaintiffs in civil litigation, a question on which US appellate courts have differed.
Akorn’s $650 million acquisition of Hi-Tech Pharmacal provides a potential long-term platform for Rx-to-OTC switches and offers additional OTC cross-selling opportunities with retailers. Akorn CEO Raj Rai calls the transaction a “transformative event” that will be instantly accretive for the firm.
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.